The stereoisomer (+)-naloxone potentiates G-protein coupling and feeding associated with stimulation of mu opioid receptors in the parabrachial nucleus

Journal of Psychopharmacology

Volumn 27, Issue 3, 2013, Pages 302-311

  Chaijale, Nayla N ^a   Aloyo, Vincent J ^a   Simansky, Kenny J ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Feeding; G protein coupling; Naloxone; Opioids; Parabrachial nucleus; Stereoselectivity

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); MU OPIATE RECEPTOR; NALOXONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEEDING; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; NONHUMAN; PARABRACHIAL NUCLEUS; PRIORITY JOURNAL; RAT; STEREOCHEMISTRY; STEREOISOMERISM;

ANALGESICS, OPIOID; ANIMALS; BEHAVIOR, ANIMAL; DRUG SYNERGISM; EATING; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; MALE; NALOXONE; NARCOTIC ANTAGONISTS; NERVE TISSUE PROTEINS; NEURONS; OSMOLAR CONCENTRATION; PONS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, MU; SIGNAL TRANSDUCTION; STEREOISOMERISM;

EID: 84877869681     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881112472561     Document Type: Article

References (56)

1. Aceto MD, Harris LS, Dewey WL, et al. (1979) Annual report: dependence studies on new compounds in the rhesus monkey. NIDA Res Monogr 27: 330-350.
2. Akil H, Watson SJ, Young E, et al. (1984) Endogenous opioids: biology and function. Annu Rev Neurosci 7: 223-255. (Pubitemid 14155298)
3. Berner LA, Bocarsly ME, Hoebel BG, et al. (2011) Pharmacological interventions for binge eating: lessons from animal models, current treatments, and future directions. Curr Pharm Des 17(12): 1180-1187.
4. Billes SK and Greenway FL (2011) Combination therapy with naltrexone and bupropion for obesity. Expert Opin Pharmacother 12(11): 1813-1826.
5. Bodnar RJ (2004) Endogenous opioids and feeding behavior: a 30-year historical perspective. Peptides 25: 697-725. (Pubitemid 38681072)
6. Buchsbaum MS, Davis GC and Bunney WE, Jr. (1977) Naloxone alters pain perception and somatosensory evoked potentials in normal subjects. Nature 270(5638): 620-622. (Pubitemid 8240781)
7. Chaijale NN, Aloyo VJ and Simansky KJ (2008) A naloxonazine sensitive (mu1 receptor) mechanism in the parabrachial nucleus modulates eating. Brain Res 1240: 111-118.
8. Chakrabarti S, Regec A and Gintzler AR (2005) Biochemical demonstration of mu-opioid receptor association with Gsalpha: enhancement following morphine exposure. Mol Brain Res 135(1-2): 217-224. (Pubitemid 40602413)
9. Chatterjie N, Sechzer JA, Lieberman KW and Alexander GJ (1998) Dextro-naloxone counteracts amphetamine-induced hyperactivity. Pharmacol Biochem Behav 59(2): 271-274. (Pubitemid 28073142)
10. Cheung CL, van Dijk M, Green JW, et al. (2007). Effects of low-dose naloxone on opioid therapy in pediatric patients: a retrospective case-control study. Intensive Care Med 33(1): 190-194. (Pubitemid 46115488)
11. Chugh PK and Sharma S (2012) Recent advances in the pathophysiology and pharmacological treatment of obesity. J Clin Pharm Ther 37(5): 525-535.
12. Cohen MR, Cohen RM, Pickar D, et al. (1985) Naloxone reduces food intake in humans. Psychosom Med 47(2): 132-138. (Pubitemid 15108846)
13. Crain SM and Shen KF (1990a). Opioids can evoke direct receptor-mediated excitatory as well as inhibitory effects on sensory neuron action potentials. NIDA Res Monogr 105: 34-39.
14. Crain SM and Shen KF (1990b) Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons. Trends Pharmacol Sci 11: 77-81. (Pubitemid 20041666)
15. Crain SM and Shen KF (1995) Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment. Proc Natl Acad Sci USA 92: 10540-10544.
16. Crain SM and Shen KF (2000) Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain 84: 121-131. (Pubitemid 30074213)
17. Denbleyker M, Nicklous DM, Wagner PJ, et al. (2009) Activating mu-opioid receptors in the lateral parabrachial nucleus increases c-Fos expression in forebrain areas associated with caloric regulation, reward and cognition. Neuroscience 162(2): 224-233.
18. DiPatrizio NV and Simansky KJ (2008) Activating parabrachial cannabinoid CB1 receptors selectively stimulates feeding of palatable foods in rats. J Neurosci 28(39): 9702-9709.
19. File SE (1980) Naloxone reduces social and exploratory activity in the rat. Psychopharmacology (Berl) 71(1): 41-44. (Pubitemid 11226283)
20. Gan TJ, Ginsberg B, Glass PS, et al. (1997) Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate. Anesthesiology 87(5): 1075-1081. (Pubitemid 27469306)
21. Gillman MA and Lichtigfeld FJ (1985) A pharmacological overview of opioid mechanisms mediating analgesia and hyperalgesia. Neurol Res 7(3): 106-119.
22. Gintzler AR, Chan WC and Glass J (1987) Evoked release of methionine enkephalin from tolerant/dependent enteric ganglia: paradoxical dependence on morphine. Proc Natl Acad Sci U S A 84(8): 2537-2539. (Pubitemid 17075901)
23. Giraudo SQ, Billington CJ and Levine AS (1998) Effects of the opioid antagonist naltrexone on feeding induced by DAMGO in the central nucleus of the amygdala and in the paraventricular nucleus in the rat. Brain Res 782(1-2): 18-23. (Pubitemid 28122976)
24. Glass MJ, Billington CJ and Levine AS (1999) Opioids and food intake: distributed functional neural pathways? Neuropeptides 33(5): 360-368. (Pubitemid 29530128)
25. Goldstein A and Naidu A (1989) Multiple opioid receptors: ligand selectivity profiles and binding site signatures. Mol Pharmacol 36(2): 265-272. (Pubitemid 19218794)
26. Guidelines for the Care and Use of Mammals in Neuroscience and BehavioralResearch. National Research Council (US) Committee on Guidelines for the Use of Animals in Neuroscience and Behavioral Research. Washington (DC): National Academies Press (US); 2003.
27. Hamann S, Sloan PA and Witt W (2008) Low-dose intrathecal naloxone to enhance intrathecal morphine analgesia: a case report. J Opioid Manag 4(4): 251-254.
28. Hussain MA, Aungst BJ, Kearney A and Shefter E (1987) Buccal and oral bioavailability of naloxone and naltrexone in rats. Int J of Pharmaceutics 36: 127-130. (Pubitemid 17070782)
29. Hutchinson MR, Zhang Y, Shridhar M, et al. (2010) Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun 24(1): 83-95.
30. Iijima I, Minamikawa J, Jacobson AE, et al. (1978) Studies in the (+)-morphinan series. 5. Synthesis and biological properties of (+)-naloxone. J Med Chem 21(4): 398-400. (Pubitemid 8324572)
31. Joshi GP, Duffy L, Chehade J, et al. (1999) Effects of prophylactic nalmefene on the incidence of morphine-related side effects in patients receiving intravenous patient-controlled analgesia. Anesthesiology 90(4): 1007-1011. (Pubitemid 29159757)
32. Kelley AE, Baldo BA and Pratt WE (2005) A proposed hypothalamic-thalamic- striatal axis for the integration of energy balance, arousal, and food reward. J Comp Neurol 493(1): 72-85. (Pubitemid 41636189)
33. La Vincente SF, White JM, Somogyi AA, et al. (2008) Enhanced buprenorphine analgesia with the addition of ultra-low-dose naloxone in healthy subjects. Clin Pharmacol Ther 83(1): 144-152.
34. Levine AS (2006) The animal model in food intake regulation: examples from the opioid literature. Physiol Behav 89(1): 92-96. (Pubitemid 44148658)
35. Levine JD, Gordon NC, Taiwo YO, Coderre TJ (1988). Potentiation of pentazocine analgesia by low-dose naloxone. J Clin Invest 82(5): 1574-1577. (Pubitemid 19007761)
36. Levine JD, Gordon NC and Fields HL (1979) Naloxone dose dependently produces analgesia and hyperalgesia in postoperative pain. Nature 278(5706): 740-741. (Pubitemid 9160278)
37. Lord JA, Waterfield AA, Hughes J, et al. (1977) Endogenous opioid peptides: multiple agonists and receptors. Nature 267(5611): 495-499. (Pubitemid 8098466)
38. Nicklous DM and Simansky KJ (2003) Neuropeptide FF exerts pro- and anti-opioid actions in the parabrachial nucleus to modulate food intake. Am. J. Physiol. Regul. Integr. Comp. Physiol. 285: R1046-R1054. (Pubitemid 37296356)
39. Paxinos G and Watson C (1998) The rat brain in stereotaxic coordinates (Academic Press, San Diego).
40. Pert CB, Danks JA, Channing MA, et al. (1984) 3-[18F]Acetylcyclofoxy: a useful probe for the visualization of opiate receptors in living animals. FEBS Lett 177(2): 281-286. (Pubitemid 15213337)
41. Ragnauth A, Moroz M and Bodnar RJ (2000) Multiple opioid receptors mediate feeding elicited by mu and delta opioid receptor subtype agonists in the nucleus accumbens shell in rats. Brain Res 876(1-2): 76-87.
42. Rice KC (1985) The development of a practical total synthesis of natural and unnatural codeine, morphine and thebaine. In: Phillipson JD., Roberts MF. and Zenk MH. (eds), The Chemistry and Biology of Isoquinoline of alkaloids. Springer-Verlag: New York. pp 191-203.
43. Schmidt JF, Chraemmer-Jørgensen B, Pedersen JE, et al. (1985) Postoperative pain relief with naloxone. Severe respiratory depression and pain after high dose buprenorphine. Anaesthesia 40(6): 583-586. (Pubitemid 15034857)
44. Shen KF and Crain SM (1989) Dual opioid modulation of the action potential duration of mouse dorsal root ganglion neurons in culture. Brain Res 491: 227-242. (Pubitemid 19163374)
45. Shen KF and Crain SM (1990a) Cholera toxin-B subunit blocks excitatory effects of opioids on sensory neuron action potentials indicating that GM1 ganglioside may regulate Gs-linked opioid receptor functions. Brain Res 531(1-2): 1-7. (Pubitemid 20348599)
46. Shen KF and Crain SM (1990b) Cholera toxin-A subunit blocks opioid excitatory effects on sensory neuron action potentials indicating mediation by Gs-linked opioid receptors. Brain Res 525(2): 225-231. (Pubitemid 20257740)
47. Sim LJ, Selley DE and Childers SR (1995) In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5'-[gamma-[35S]thio]-triphosphate binding, Proc Natl Acad Sci 92: 7242-7246.
48. Sim LJ, Selley DE, Dworkin SI and Childers SR (1996) Effects of chronic morphine administration on mu opioid receptor-stimulated [35S]GTPgammaS autoradiography in rat brain. J Neurosci 16(8): 2684-2692.
49. Taiwo YO, Basbaum AI, Perry F, et al. (1989) Paradoxical analgesia produced by low doses of the opiate-antagonist naloxone is mediated by interaction at a site with characteristics of the delta opioid receptor. J Pharmacol Exp Ther 249(1): 97-100.
50. Tsai RY, Tai YH, Tzeng JI, et al. (2009) Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxin-treated rats by reversing the coupling of mu-opioid receptors from Gs-protein to coupling to Gi-protein. Neuroscience 164(2): 435-443.
51. Wang HY, Friedman E, Olmstead MC, et al. (2005) Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling. Neuroscience 135(1): 247-261. (Pubitemid 41219753)
52. Wang HY and Burns LH (2009) Naloxone's pentapeptide binding site on filamin A blocks Mu opioid receptor-Gs coupling and CREB activation of acute morphine. PLoS One 4(1): e4282.
53. Ward HG and Simansky KJ (2006a) Chronic prevention of mu-opioid receptor (MOR) G-protein coupling in the pontine parabrachial nucleus persistently decreases consumption of standard but not palatable food. Psychopharmacology (Berl) 187: 435-446. (Pubitemid 44200515)
54. Ward HG and Simansky KJ (2006b) Regional specialization of mu-opioid receptors within the parabrachial nucleus of the pons in modulating eating. Society for Neuroscience annual meeting. October 2006. Atlanta, GA.
55. Wilson JD, Nicklous DM, Aloyo VJ, et al. (2003) An orexigenic role for mu-opioid receptors in the lateral parabrachial nucleus. Am J Physiol Regul Integr Comp Physiol 285(5): R1055-1065. (Pubitemid 37296357)
56. Zimmerman DM and Leander JD (1990) Selective opioid receptor agonists and antagonists: research tools and potential therapeutic agents. J Med Chem 33(3): 895-902. (Pubitemid 20085889)